drugset / Trial / NCT03084380
Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC)
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to evaluate the safety and efficacy of anti-GPC3 scFv-41BB-CD3ζ-tEGFR chimeric antigen receptor (CAR)-modified T (CAR-T) cells in treating patients with GPC3-positive advanced hepatocellular carcinoma (HCC).
Timeline
- Start
- 2017-06-01
- Primary completion
- 2019-05-31
- Completion
- 2020-05-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Retroviral vector-transduced autologous T cells to express anti-GPC3 CARs | Cell therapy | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 40 mg/kg | — |
| Background | Fludarabine | Small molecule | 25 mg/m2 | — |